OBIO
NASDAQOrchestra BioMed Holdings Inc.
Price$5.43-0.14 (-2.42%)
01:45 PM07:45 PM
News · 26 weeks60-67%
2026-04-192026-10-11
Mix2490d
- Insider11(46%)
- SEC Filings6(25%)
- Other6(25%)
- Analyst1(4%)
Latest news
25 items- INSIDEROfficer Sherman Darren sold $95,400 worth of shares (15,000 units at $6.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,119,402 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form 144 filed by Orchestra BioMed Holdings Inc.144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- SECOrchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- PROrchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies NEW HOPE, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading medical device companies, today announced that it has surpa
- PROrchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by HaemoneticsPayment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical d
- INSIDEROfficer Hochman David P covered exercise/tax liability with 6,566 shares, decreasing direct ownership by 0.31% to 1,067,463 units (SEC Form 4) (tax withholding)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- ANALYSTOrchestra BioMed upgraded by BTIG Research with a new price targetBTIG Research upgraded Orchestra BioMed from Neutral to Buy and set a new price target of $10.00
- SECOrchestra BioMed Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- INSIDEROfficer Hochman David P bought $47,900 worth of shares (10,000 units at $4.79), increasing direct ownership by 0.94% to 1,070,746 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Sherman Darren sold $74,100 worth of shares (15,000 units at $4.94) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,134,402 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on September 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 133,000 shares of the Company’s common stock to seven newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment
- SECSEC Form 144 filed by Orchestra BioMed Holdings Inc.144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- INSIDERChief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,076 shares, decreasing direct ownership by 0.52% to 589,989 units (SEC Form 4) to cover taxes4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERPrincipal Accounting Officer Aiello Joshua covered exercise/tax liability with 203 shares, decreasing direct ownership by 1% to 18,441 units (SEC Form 4) to satisfy withholding tax4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDEROfficer Sherman Darren bought $10,660 worth of shares (2,000 units at $5.33) and covered exercise/tax liability with 4,925 shares, decreasing direct ownership by 0.43% to 1,149,402 units (SEC Form 4) to satisfy tax liability4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceNEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, Sept. 16, 2026 at 9:00am ET, and will also host one-on-one meetings with investors that day. About Orchestra BioMedOrchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. Th
- PROrchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare ConferenceNEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also host one-on-one meetings with investors that day and on Wednesday, Sept. 9. A live webcast of the event will be accessible through Orchestra BioMed’s Investor Relations website and will be available for replay following the event. About Orchestra BioMedOrchestra BioMed is a b
- INSIDERDirector Mack John Prosper covered exercise/tax liability with 4,885 shares, decreasing direct ownership by 7% to 66,544 units (SEC Form 4) (tax liability)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Fain Eric S covered exercise/tax liability with 5,145 shares (SEC Form 4) (withholding obligation)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- INSIDERDirector Pacitti David covered exercise/tax liability with 3,761 shares, decreasing direct ownership by 6% to 54,750 units (SEC Form 4) to satisfy withholding tax4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- PROrchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesThe BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation targeted for Q2 2027, assuming those endpoints are met.Virtue pivotal trial is advancing with further site activations and patient enrollments. $110 million cash balance provides projected runway into Q4 2027 and through key upcoming milestones, following $35 million in strategic capital from Medtronic and Ligand.Company to host R&D Day on November 12, 2026, in New York City, featuring in-depth reviews of both the AVIM Therapy and Virtue SAB programs. NEW HOPE, Pa., Aug. 10, 20
- SECSEC Form 10-Q filed by Orchestra BioMed Holdings Inc.10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)
- INSIDEROfficer Sherman Darren sold $61,350 worth of shares (15,000 units at $4.09) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,154,327 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
- SECSEC Form 144 filed by Orchestra BioMed Holdings Inc.144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)
- INSIDEROfficer Sherman Darren sold $64,050 worth of shares (15,000 units at $4.27) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,169,327 units (SEC Form 4)4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)
OBIO FAQ
6 questionsWhere does OBIO stock trade?
Orchestra BioMed Holdings Inc. (OBIO) is listed on NASDAQ.What sector and industry is OBIO in?
Orchestra BioMed Holdings Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.When did Orchestra BioMed Holdings Inc. go public?
Orchestra BioMed Holdings Inc. (OBIO) completed its IPO in 2020.What are analysts saying about OBIO?
Orchestra BioMed Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1000.00 price target on 2026-09-10. Recent price targets range from $1000.00 to $1600.00.What companies are similar to OBIO?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), DFTX (Definium Therapeutics Inc.), RGC (Regencell Bioscience Holdings Limited). Compare OBIO side-by-side with any of them on Quantisnow.How can I track OBIO on Quantisnow?
Quantisnow aggregates Orchestra BioMed Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OBIO to receive live email and push alerts on every new disclosure.